Value of concentration and gene methylation analyses of circulating cell-free DNA as diagnostic method for breast cancer: a systematic review

被引:0
|
作者
Zhu, Xiao [1 ]
Huang, Junming [2 ]
Zhang, Kun [3 ]
Yu, Yinghua [1 ]
机构
[1] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Breast Surg, 71 Hedi Rd, Nanning 530021, Guangxi, Peoples R China
[2] Panyu Hosp Chinese Med, Dept Oncol, Guangzhou, Guangdong, Peoples R China
[3] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Breast Surg, Yantai, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2018年 / 11卷 / 08期
关键词
Breast neoplasms; circulating cell-free DNA; concentration; methy at on; meta-analysis; PROMOTER METHYLATION; ODDS RATIO; TUMOR DNA; PLASMA; SERUM; HYPERMETHYLATION; METASTASIS; CARCINOMA; ACCURACY; MARKER;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background and aims: Many studies focus attention on circulating cell-free DNA (cfDNA) concentration and methylation as means for early detection of breast cancer. However, the results of existing studies are different and it remains difficult to determine the diagnostic role of circulating cfDNA in breast cancer. Therefore, this study performed a meta-analysis to integrate the findings of these published studies and establish the diagnostic value of circulating cfDNA in diagnosis of breast cancer. Methods: A total of 19 studies were included and divided into three subgroups. Sensitivity, specificity, and other important measures of cfDNA accuracy for breast cancer diagnosis were pooled using random-effects models. Summary receiver operating characteristic curve analysis techniques were used to summarize overall accuracy. Results: Summary estimates for cfDNA concentration and gene methylation in diagnosis of breast cancer were as follows: in the subgroup of quantitative analysis, sensitivity and specificity were 0.889 (95%CI = 0.858-0.915) and 0.806 (95%CI = 0.767-0.841); PLR was 5.058 (95%Cl = 2.723-9.392); NLR was 0.150 (95% CI = 0.090-0.251) and DOR value was 42.156 (95% CI = 19.364-91.774). In the subgroup of single-gene indicators, sensitivity and specificity were 0.406 (95%CI = 0.390-0.421) and 0.848 (95% CI = 0.836-0.860); PLR was 4.569 (95% CI = 3.329-6.270); NLR was 0.643 (95% CI = 0.588-0.704) and DOR value was 8.608 (95% CI = 5.679-13.046). In the subgroup of multiple-gene panel, sensitivity and specificity were 0.778 (95% CI = 0.760-0.796) and 0.835 (95% CI = 0.819-0.850); PLR was 6.158 (95% CI = 4.432-8.556); NLR was 0.194 (95% CI = 0.139-0.272) and DOR value was 39.353 (95% CI = 21.139-73.260). Conclusion: Circulating cfDNA concentration and gene methylation analysis might be applied in breast cancer detection since the test has a relatively high level of diagnostic accuracy. If only the single-gene methylation detection assay is used for breast cancer diagnosis, extra caution should be applied. Evaluation of circulating cfDNA concentration and multiple-gene methylation analyses might improve breast cancer early diagnosis.
引用
收藏
页码:7519 / +
页数:14
相关论文
共 50 条
  • [41] Diagnostic value of circulating cell-free DNA for renal cell carcinoma: a meta-analysis
    Li, Yong
    Chen, Peng
    Chen, Zhi
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (05) : 2265 - +
  • [42] Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer
    Gong, Bo
    Xue, Jianxiang
    Yu, Jing
    Li, Haichuan
    Hu, Heyu
    Yen, Hsuehheng
    Hu, Jinyin
    Dong, Qianggang
    Chen, Fuhua
    ONCOLOGY LETTERS, 2012, 3 (04) : 897 - 900
  • [43] Comparison of enzymatic and bisulfite conversion of circulating cell-free tumor DNA for DNA methylation analyses
    Stine H. Kresse
    Evy Marie Thorkildsen
    Sara Brandt-Winge
    Heidi Pharo
    Hege Marie Vedeld
    Guro E. Lind
    Clinical Epigenetics, 17 (1)
  • [44] The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients
    Bonlokke, Sara
    Stougaard, Magnus
    Sorensen, Boe Sandahl
    Booth, Berit Bargum
    Hogdall, Estrid
    Nyvang, Gitte-Bettina
    Lindegaard, Jacob Christian
    Blaakaer, Jan
    Bertelsen, Jesper
    Fuglsang, Katrine
    Strube, Mikael Lenz
    Lenz, Suzan
    Steiniche, Torben
    CELLS, 2022, 11 (14)
  • [45] The Prognostic Value of Plasma Cell-Free DNA Concentration in the Prostate Cancer: A Systematic Review and Meta-Analysis
    Liu, Hongtao
    Gao, Yuzhen
    Vafaei, Somayeh
    Gu, Xiao
    Zhong, Xiaoli
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma
    Elzehery, Rasha
    Effat, Narmin
    El Farahaty, Reham
    Farag, Raghda Elsayed
    Abo-Hashem, Ekbal M.
    Elhelaly, Rania
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2022, 158 (02) : 254 - 262
  • [47] Aberrant Telomere Length in Circulating Cell-Free DNA as Possible Blood Biomarker with High Diagnostic Performance in Endometrial Cancer
    Benati, Marco
    Montagnana, Martina
    Danese, Elisa
    Mazzon, Martina
    Paviati, Elisa
    Garzon, Simone
    Lagana, Antonio Simone
    Casarin, Jvan
    Giudici, Silvia
    Raffaelli, Ricciarda
    Ghezzi, Fabio
    Franchi, Massimo
    Lippi, Giuseppe
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2281 - 2289
  • [48] Quantification of Plasma Cell-Free Circulating DNA at Different Stages of Colorectal Cancer
    Agah, Shahram
    Akbari, Abolfazl
    Talebi, Atefeh
    Masoudi, Mohsen
    Sarveazad, Arash
    Mirzaei, Alireza
    Nazmi, Farinaz
    CANCER INVESTIGATION, 2017, 35 (10) : 625 - 632
  • [49] Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: A meta-analysis
    Zhang, Ruifeng
    Shao, Fangchun
    Wu, Xiaohong
    Ying, Kejing
    LUNG CANCER, 2010, 69 (02) : 225 - 231
  • [50] Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management
    Hassan, Sadia
    Shehzad, Adeeb
    Khan, Shahid Ali
    Miran, Waheed
    Khan, Salman
    Lee, Young-Sup
    BIOMEDICINES, 2022, 10 (08)